Quality-of-Life Questionnaires Sent to 181 Workers With Occupational Contact Dermatitis
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional workplace scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
This review asks one narrow workplace question and keeps the paper’s population, denominator, design, timepoint, result and uncertainty attached. It is education, not a diagnosis or individualized occupational-safety plan.
What did the study actually examine?
| Study element | Reported detail |
|---|---|
| Population | 181 patients diagnosed with occupational contact dermatitis during 1996-1999; 70 responded (39%). |
| Design | Postal DLQI and SF-36 survey after occupational-contact-dermatitis diagnosis. |
| Timepoint | Questionnaire after diagnoses made across a three-year period. |
| Key result | Among 70 respondents, median DLQI was 5 and mean 6.6 (SD 6.4); symptoms and feelings were the most problematic domains, and SF-36 linked physical and emotional problems affecting work. |
| Funding/conflicts available in the record | The historical abstract did not provide funding or conflict information. |
How should the main finding be read?
Among 70 respondents, median DLQI was 5 and mean 6.6 (SD 6.4); symptoms and feelings were the most problematic domains, and SF-36 linked physical and emotional problems affecting work.
The response denominator, not just the mailed denominator, is essential when reading these burden estimates.
The denominator matters. Some papers began with an entire workforce, while others included referred patients, recognized claims or people selected for testing. A percentage from one of those groups cannot automatically be applied to everyone in the occupation.
Why are symptoms, examination and testing different?
A symptom report can identify a pattern worth evaluating, but it is not the same as a clinician-confirmed diagnosis. A positive patch test identifies delayed sensitization under standardized conditions; occupational relevance still depends on exposure, distribution and timing. Contact urticaria, irritant dermatitis, allergic contact dermatitis and atopic dermatitis can also overlap or require different tests.
For outbreak reports, the workplace investigation may be the most important part of the evidence. Measuring a concentration, reviewing a safety data sheet, analysing a product or comparing exposed tasks can identify prevention targets that a skin-care routine cannot address.
What are the most important limitations?
The 39% response rate creates substantial nonresponse risk, the study lacked an unexposed comparator, and recalled burden may differ by time since diagnosis.
The historical abstract did not provide funding or conflict information. Absence of a funding statement in an abstract is not proof that no funding or competing interest existed; it means the accessible record did not provide enough detail to make a stronger claim.
What can a worker document before an appointment?
- The exact task, material, cleanser, glove, resin, dye, metal, food, dust, adhesive or equipment used.
- Where symptoms appear, when they begin, and whether they change on days away or after a process change.
- Product labels and safety data—without placing workplace substances directly on the skin.
- Required PPE, handwashing frequency, heat, friction, sweating and wet-work duration.
- Changes in function, sleep, attendance or the ability to complete specific tasks.
What does prevention require?
Exposure controls, substitution, engineering measures, training and correctly selected protective equipment belong in the conversation with occupational health and the employer. Gloves themselves can contain allergens, so “wear gloves” is not a complete plan without matching glove material and task. Skin-care products do not replace source control. Seek prompt medical care for severe pain, rapidly spreading redness, drainage, fever, breathing symptoms or major loss of function.
Primary research and guidance
- Primary research record: PubMed PMID 11422262
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis overview
- American Academy of Dermatology: eczema skin care
PubMed indexing is not NIH endorsement of the study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine. This article makes no treatment, cure, prevention, itch-relief, pediatric-safety, universal-tolerance or 24-hour claim.
Bottom line
This evidence is most useful when its population, denominator and design travel with the number. Use it to sharpen questions about diagnosis, exposure and work design—not to promise that one routine works for every person or job.
DR. ARSY SKINCARE
Shop Moisturizer #003
Choose your preferred place to shop.